Article
REGENXBIO's Clinical Trial for Duchenne Therapy RGX-202 Begins Patient Recruitment
Author(s):
Recruitment has begun for REGENXBIO's AFFINITY BEYOND clinical trial assessing the prevalence of AAV8 antibodies in male patients with Duchenne muscular dystrophy.
Aravindhan Veerapandiyan, MD
This content was originally published on CGTLive, a sister publication. Click here to view.
News from REGENXBIO, as the company recently announced the start of patient recruitment for the phase 1/2 AFFINITY DUCHENNE clinical trial (NCT05693142) for RGX-202, an investigational adeno-associated virus (AAV) vector-based gene therapy for Duchenne muscular dystrophy (DMD).1 The data collected from this trial could possibly be used to identify potential participants for the AFFINITY DUCHENNE trial and potential future trials of RGX-202.
The multicenter, open-label, AFFINITY DUCHENNE trial will initially seek to recruit 6 patients aged 4 to 11 years with DMD who are ambulatory. The patients will be divided into 2 cohorts that include 3 patients each, with the lower-dose cohort receiving 1x1014 genome copies (GC)/kg body weight and the higher-dose cohort receiving 2x1014 GC/kg body weight. The study may recruit an additional 9 patients at a later time based on the results of an independent safety data review.
"I am pleased that we are now able to initiate the trial for RGX-202 and also begin enrollment activities in our AAV8 antibody screening study," Kenneth T. Mills, president and chief executive officer, REGENXBIO, said in a statement.1 "The RGX-202 program is a key piece of our '5x'25' strategy to have 5 AAV therapeutics either on the market or in late-stage development by 2025. We look forward to continuing to work closely with the Duchenne community as we advance a highly differentiated product candidate developed with the potential to improve muscle strength and motor function in boys with Duchenne."
RGX-202 uses REGENXBIO’s proprietary NAV AAV8 vector and is intended to deliver a novel transgene which contains the functional elements of the C-Terminal (CT) domain seen in natural dystrophin.1 The company has noted that the CT domain's presence “has been shown in preclinical studies to recruit several key proteins to the muscle cell membrane, leading to improved muscle resistance to contraction-induced muscle damage in dystrophic mice.”1
Participants in the trial will be required to have a DMD gene mutation in exons 18 and above, must be able to walk 100 meters independently without assistive devices, must be able to complete the Time to Stand Test per protocol-specific criteria, and must be on a stable dose of systemic glucocorticoids according to the standard of care for at least 12 weeks prior to screening.
Patients with detectable AAV8 total binding antibodies in serum, those with a left ventricular ejection fraction on screening of less than 55%, those who have received ataluren or an exon-skipping therapy for the treatment of DMD within 6 months of entry into the study, and those who are unable to cease taking ataluren or exon-skipping therapy for 5 years from the time of RGX-202's administration will be excluded from the study. Additional exclusion criteria relate to patient health status, treatment-history, and investigator discretion.
The study’s primary end point is the incidence of adverse events (AE) and serious AEs. Secondary end points include changes in North Star Ambulatory Assessment raw and total score, microdystrophin protein expression, and measures of pharmacokinetics and vector shedding. Participants in the trial will receive a prophylactic immunosuppression regimen intended to mitigate potential complement-mediated immune responses. The trial will begin at sites in the United States, with sites in Canada and Europe expected to open later on.
"DMD is a devastating disease and there are still unmet therapeutic needs," Aravindhan Veerapandiyan, MD, a principal investigator in the study and director of the Comprehensive Neuromuscular Program, PPMD Certified Duchenne Care Center, and co-director of the Muscular Dystrophy Association Care Center at Arkansas Children's Hospital, added to the statement.1 "Gene therapies, like RGX-202, have the potential to impact the progressive nature of Duchenne."
The initiation of the AFFINITY DUCHENNE trial was originally expected to being in the first half of 2022, following the FDA’s clearance of RGX-202's investigational new drug application in January of that year.2 However, the trial was delayed due to an “unexpected and isolated observation” that occurred during the vial-filling stage of the manufacturing process at a third-party manufacturing facility.3 Alongside AFFINITY DUCHENNE, REGENXBIO has also initiated recruitment for AFFINITY BEYOND, an observational study assessing the prevalence of AAV8 antibodies in male patients under the age of 12 years with DMD.1
